COVID-19 Impact on Global Influenza Diagnostics Market
The emergence of the COVID-19 pandemic has changed the delivery of medical care across the world. The COVID-19 pandemic has significantly affected the influenza diagnostics market; unfavorable changes in regulations and guidelines, the closing of manufacturing facilities due to lockdowns and disruptions in supply chains have severely affected the market growth. In addition, limited operations in most industries, inadequate funding for research and academic institutes, and challenges in providing essential/post-sales services due to lockdowns have reduced the supply of influenza diagnostics products to end users. Furthermore, there are many similarities between influenza and COVID-19; both seasonal flu (influenza A and B) and COVID-19 are contagious viruses and show similar symptoms of respiratory illness. Influenza outbreaks generally occur from December to February. The COVID-19 outbreak also occurred during the influenza season, resulting in the increased adoption of influenza tests during this period.
Influenza Diagnostics Market Overview:
The Influenza Diagnostics Market is projected to reach USD 1.1 billion by 2026 from USD 0.8 billion in 2021, at a CAGR of 7.7%. Market growth is driven by rising demand for rapid disease diagnosis, increasing prevalence of influenza and growth in influenza research for diagnostic technologies.
The global influenza diagnostics market is projected to reach USD 1.1 billion by 2026 from USD 0.8 billion in 2021, at a CAGR of 7.7% during the forecast period. Growth in the influenza diagnostics market is mainly driven by factors such as the increasing prevalence of influenza, Growth in influenza research for diagnostic technologies and Rising demand for rapid disease diagnosis. However, variabilities in test sensitivity and specificity and rising healthcare costs are the major factors hampering the growth of this market.
Request For Sample: https://www.marketsandmarkets.com/requestsampleNew.asp?id=222985562
In 2020, molecular diagnostic tests segment accounted for the largest share of the influenza diagnostics market, by test type
The influenza diagnostics market is segmented into molecular diagnostics tests and traditional diagnostic tests based on test type. In 2020, the molecular diagnostic tests segment accounted for the largest share. Factors such as growth in influenza research for diagnostic technologies and increasing prevalence of influenza drive this market.
In 2020, diagnostic laboratories segment accounted for the largest share in the influenza diagnostics market, by end users
The influenza diagnostics market has been segmented into diagnostic laboratories, hospitals and clinics and other end users based on end users. In 2020, the diagnostic laboratories segment accounted for the largest share of the influenza diagnostics market. Increasing prevalence of influenza and rising demand for rapid disease diagnosis is driving the growth of this segment.
Molecular Diagnostic Tests segment to register the highest growth rate during the forecast period
The influenza diagnostics market is segmented into traditional diagnostic test (rapid influenza diagnostic tests, viral culture tests, direct fluorescent antibody test, serological tests) and molecular diagnostic tests (polymerase chain reaction, isothermal nucleic acid amplification tests(transcription-mediated amplification-based assay, loop-mediated isothermal amplification-based assay, nucleic acid sequence-based amplification tests, other isothermal nucleic acid amplification tests) and other molecular diagnostic tests. In 2020, the molecular diagnostic tests segment accounted for the highest growth rate. Factors such as the rising demand for rapid disease diagnosis drive this market and growth in influenza research for diagnostic technologies.
The major players in this market are Danaher Corporation (US), Siemens Healthineers (Germany), Thermo Fisher Scientific, Inc. (US), F. Hoffmann-LA Roche AG (Switzerland), Abbott Laboratories, Inc. (Us), Hologic, Inc. (US), bioMérieux SA (France), Quidel Corporation (US), Becton, Dickinson and Company (US), Meridian Bioscience (US), GenMark Diagnostics, Inc. (US), Luminex Corporation (US), Tecan Trading AG (Switzerland), DiaSorin SA (Italy), altona Diagnostics GmbH (Germany), SEKISUI Diagnostics (US), SA Scientific Ltd. (US), Coris BioConcept SPRL (Belgium), ELITech Group (France), Mast Group Ltd. (UK), Genome Diagnostics, Pvt. Ltd. (India), Germaine Laboratories, Inc. (US), Response Biomedical Corp. (Canada). Tauns Laboratories, Inc. (Japan) and 3B BlackBio Biotech India Ltd. (India)
Mr. Aashish Mehra
630 Dundee Road
Northbrook, IL 60062
USA : 1–888–600–6441